Biomea Fusion Balance Sheet Health

Financial Health criteria checks 6/6

Biomea Fusion has a total shareholder equity of $15.6M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $55.2M and $39.6M respectively.

Key information

Debt to equity ratio

US$0

Debt

Interest coverage ratio	n/a
Cash	US$46.64m
Equity	US$15.62m
Total liabilities	US$39.57m
Total assets	US$55.19m

Recent financial health updates

Recent updates

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Oct 07

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Aug 17

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Sep 30

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Jun 10

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Feb 22

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Nov 07

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Jul 12

Here's Why We're Not Too Worried About Biomea Fusion's (NASDAQ:BMEA) Cash Burn Situation

Mar 29

We're Hopeful That Biomea Fusion (NASDAQ:BMEA) Will Use Its Cash Wisely

Nov 03

Financial Position Analysis

Short Term Liabilities: BMEA's short term assets ($49.4M) exceed its short term liabilities ($15.6M).

Long Term Liabilities: BMEA's short term assets ($49.4M) exceed its long term liabilities ($24.0M).

Debt to Equity History and Analysis

Debt Level: BMEA is debt free.

Reducing Debt: BMEA has no debt compared to 5 years ago when its debt to equity ratio was 0.4%.

Balance Sheet

Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: BMEA has sufficient cash runway for 6 months based on last reported free cash flow, but has since raised additional capital.

Forecast Cash Runway: BMEA is forecast to have sufficient cash runway for 7 months based on free cash flow estimates, but has since raised additional capital.

Discover healthy companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/02/15 10:29
End of Day Share Price	2026/02/13 00:00
Earnings	2025/09/30
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Biomea Fusion, Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Naureen Quibria	Capital One Securities, Inc.
Yigal Nochomovitz	Citigroup Inc
Jason Kolbert	D. Boral Capital LLC.

Biomea Fusion Balance Sheet Health

Financial Health criteria checks 6/6

Key information

Recent financial health updates

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

Recent updates

Biomea Fusion, Inc. Presents Covid-111 Study Results At the 23Rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease

Co-Founder recently bought US$55k worth of stock

Biomea Fusion, Inc. Showcases Preclinical Advances for BMF-650 and Icovamenib with Low Dose Semaglutide At Obesityweek®? 2025

Price target decreased by 10% to US$7.17

Biomea Fusion, Inc. Announces Impairment Charges for the Three Months Ended September 30, 2025

Biomea Fusion, Inc. Announces First Patient Dosed in Phase I Study of BMF-650 A Next-Generation Oral GLP-1 Receptor Agonist

Biomea Fusion Announces Positive 52-Week Results from Phase II Covid-111 Study in Type 2 Diabetes Demonstrating Non-Chronic Treatment with Icovamenib Benefits Two Distinct Patient Populations

Biomea Fusion: Surging On Data, Sinking On Funding - I'm On The Sidelines

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion, Inc. Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes (T2D) Animal Model

Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?

Price target decreased by 27% to US$8.29

Biomea Fusion, Inc. Announces Board Changes

Biomea Fusion, Inc.(NasdaqGS:BMEA) dropped from Russell 2000 Index

Biomea Fusion, Inc. Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association (ADA)

New major risk - Shareholder dilution

Biomea Fusion, Inc. has filed a Follow-on Equity Offering.

Biomea Fusion Presents Updated Preliminary Clinical Data for Covalent Flt3 Inhibitor Bf-500 in Relapsed or Refractory Acute Leukemia At Eha 2025

New major risk - Share price stability

Price target decreased by 14% to US$20.00

Biomea Fusion, Inc. Selects for Poster Presentation at EHA 2025 Highlighting Phase I Data in Relapsed/Refractory Acute Leukemia

Price target decreased by 13% to US$20.50

Biomea Fusion, Inc., Annual General Meeting, Jun 11, 2025

Biomea Fusion, Inc. Auditor Raises 'Going Concern' Doubt

Biomea Fusion, Inc. Announces Chief Executive Officer Changes

Biomea Fusion Inc. Announces Icovamenib Treatment in Patients with Severe Insulin-Deficient Diabetes Led to a Significant Improvement in Pancreatic Beta-Cell Function with a 53% Mean Increase in C-peptide Levels 3 Months After Last Dose

New major risk - Revenue and earnings growth

New minor risk - Market cap size

Price target decreased by 34% to US$28.11

Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study

Biomea Fusion Announces Positive Topline Results from Ongoing Phase II COVALENT-111 Study in Patients with Type 2 Diabetes

Biomea Fusion, Inc. Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia

Biomea Fusion, Inc. Presents the New Analysis from the Escalation Portion of COVALENT-111 at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management

Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate

High number of new and inexperienced directors

Independent Director recently bought US$101k worth of stock

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

We're Keeping An Eye On Biomea Fusion's (NASDAQ:BMEA) Cash Burn Rate

Biomea Fusion, Inc. Announces FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

New major risk - Financial position

High number of new and inexperienced directors

CFO & Principal Accounting Officer recently bought US$55k worth of stock

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully

Price target decreased by 17% to US$41.00

Biomea Fusion, Inc. Announces BMF-219 in Diabetes Placed on Clinical Hold

New major risk - Share price stability

Biomea Fusion, Inc. Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

Price target increased by 10% to US$54.43

Biomea Fusion, Inc., Annual General Meeting, Jun 12, 2024

Biomea Fusion, Inc. Announces Initial Response Data from the First Two Type 1 Diabetes Patients Treated with Bmf-219 in the Ongoing Phase Ii Study (Covalent-112)

Price target decreased by 9.2% to US$49.38

Biomea Fusion, Inc. Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

We Think Biomea Fusion (NASDAQ:BMEA) Can Afford To Drive Business Growth

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase Ii Study (Covalent-112) with BMF-219

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Presents Long-Term Follow-Up Data Showing Improved Glycemic Control After 22 Weeks Off Treatment in Ongoing Phase II Study (COvalent-111) of BMF-219 in Adults with Type 2 Diabetes in A Poster Presentation at the World Congress Insulin Resistance, Diabetes

Biomea Fusion, Inc. Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes

New minor risk - Share price stability

Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

Is Biomea Fusion (NASDAQ:BMEA) In A Good Position To Invest In Growth?

New major risk - Revenue and earnings growth

Biomea Fusion Announces Two Poster Presentations At Upcoming Ash Annual Meeting 2023

Biomea Fusion, Inc. Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)

Biomea Fusion Announces Fda and Health Canada Clearance of the Expansion Cohorts of the Ongoing Covvalent-111 Phase Ii Study

Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Biomea Fusion, Inc. Announces Preliminary Topline Data from Its Ongoing Phase I Clinical Trial, Covalent-101, Showcasing Initial Responses in Relapsed/Refractory Aml Patients with Menin-Dependent Mutations

We Think Biomea Fusion (NASDAQ:BMEA) Needs To Drive Business Growth Carefully